itraconazol
itz
wellknown
antifung
agent
also
anticanc
activ
studi
identifi
itz
broadspectrum
inhibitor
enterovirus
eg
polioviru
coxsackieviru
rhinoviru
demonstr
itz
inhibit
viral
rna
replic
target
oxysterolbind
protein
osbp
osbprel
protein
consist
specif
antagonist
also
inhibit
enteroviru
replic
knockdown
osbp
inhibit
viru
replic
wherea
overexpress
osbp
counteract
antivir
effect
itz
itz
bind
osbp
inhibit
function
ie
shuttl
cholesterol
membran
therebi
like
perturb
virusinduc
membran
alter
essenti
viral
replic
organel
format
itz
also
inhibit
hepat
c
viru
replic
also
reli
osbp
togeth
data
implic
novel
molecular
target
itz
point
essenti
role
lipid
exchang
viru
replic
target
antivir
drug
famili
picornavirida
contain
mani
import
human
anim
pathogen
genu
enteroviru
includ
polioviru
pv
coxsackieviru
cv
echoviru
sever
number
enterovirus
eg
human
rhinoviru
hrv
except
pv
vaccin
avail
prevent
infect
enterovirus
antivir
drug
avail
treatment
import
human
picornavirus
includ
hepat
viru
human
parechoviru
hpev
wellknown
anim
pathogen
footandmouth
diseas
viru
fmdv
encephalomyocard
viru
emcv
genom
enterovirus
consist
singlestrand
rna
molecul
posit
polar
rna
encod
singl
polyprotein
proteolyt
process
viral
proteas
structur
protein
nonstructur
protein
viral
genom
replic
assembl
viral
host
protein
locat
intracellular
membran
term
replic
organel
ro
ro
form
result
virusinduc
remodel
secretori
pathway
membran
like
start
golgi
complex
hsu
et
al
eventu
result
complex
network
tubulovesicular
membran
belov
et
al
limpen
et
al
viral
modif
lipid
homeostasi
thought
play
major
role
ro
format
viral
protein
play
major
role
membran
rearrang
recruit
essenti
host
factor
enteroviru
replic
ro
iii
beta
golgiloc
lipid
kinas
gener
phosphat
arita
hsu
et
al
function
import
elev
level
ro
remain
establish
viral
rnadepend
rnapolymeras
pol
bind
vitro
unknown
whether
import
recruit
andor
activ
infect
cell
hsu
et
al
altern
lipid
may
particip
ro
format
facilit
recruit
host
protein
membranemodifi
properti
cholesterol
critic
membran
compon
determin
membran
fluiditi
regul
format
function
membranebound
complex
lipid
protein
sever
rna
virus
hepat
c
viru
hcv
dengu
west
nile
viru
remodel
cellular
cholesterol
landscap
make
intracellular
host
cell
membran
conduc
effici
genom
replic
rothwel
et
al
wang
et
al
enterovirusinduc
rearrang
secretori
pathway
membran
tubulovesicular
ro
structur
may
also
depend
alter
cholesterol
homeostasi
recent
data
suggest
enterovirus
stimul
clathrinmedi
endocytosi
transport
cholesterol
plasma
membran
extracellular
medium
ro
ilnytska
et
al
howev
intracellular
cholesterol
traffick
pathway
may
also
subvert
enterovirus
creat
ro
recent
oxysterolbind
protein
osbp
show
play
key
role
transport
cholesterol
er
golgi
mesmin
et
al
osbp
link
er
transgolgi
membran
socal
ergolgi
membran
contact
site
mc
shuttl
sterol
golgi
back
er
hydrolyz
exchang
cycl
drive
deliveri
sterol
transgolgi
selfregul
local
osbp
golgi
osbp
osbprel
protein
orp
constitut
famili
relat
protein
base
gene
structur
sequenc
subdivid
six
subfamili
osbp
closest
rel
also
call
belong
subfamili
orp
lipidbind
domain
initi
thought
specif
sterol
howev
recent
structur
analysi
suggest
orp
abil
bind
second
lipid
either
sterol
nonsterol
ligand
mani
orp
includ
osbp
ffatmotif
recogn
erresid
vap
receptor
ntermin
pleckstrin
homolog
ph
domain
bind
link
varieti
organel
although
function
orp
well
understood
becom
clear
orp
execut
divers
function
lipid
sens
lipid
transport
cell
signal
raychaudhuri
prinz
weberboyvat
et
al
set
identifi
novel
inhibitor
enteroviru
replic
screen
nih
clinic
collect
ncc
librari
fdaapprov
drug
histori
use
clinic
trial
treatment
wide
varieti
diseas
similar
collect
fdaapprov
drug
proven
rich
sourc
undiscov
bioactiv
therapeut
potenti
identifi
itraconazol
itz
broadspectrum
inhibitor
enteroviru
replic
itz
wellknown
antifung
drug
inhibit
cytochrom
requir
sterol
biosynthesi
lestner
hope
addit
itz
exert
anticanc
activ
inhibit
angiogenesi
disturb
mtor
signal
vascular
endotheli
growth
factor
receptor
traffick
hedgehog
hh
signal
pathway
kim
et
al
nacev
et
al
xu
et
al
itz
found
efficaci
patient
sever
cancer
type
multipl
phase
clinic
studi
antonaraki
et
al
kim
et
al
rudin
et
al
demonstr
known
target
itz
explain
antivir
activ
itz
instead
evid
present
osbp
novel
target
itz
direct
bind
itz
osbp
local
ro
disrupt
lipid
shuttl
function
account
antivir
effect
itz
perform
screen
ncc
identifi
novel
inhibitor
replic
like
enterovirus
kill
host
cell
therebi
caus
cytopath
effect
cpe
screen
ncc
microscop
observ
compound
prevent
develop
cpe
multicycl
replic
assay
identifi
itz
figur
one
hit
determin
spectrum
antivir
activ
test
itz
repres
panel
picornavirus
multicycl
cpereduct
assay
itz
exhibit
antivir
effect
enterovirus
examin
belong
sever
speci
ec
valu
tabl
addit
emcv
cardioviru
genu
member
inhibit
itz
contrast
equin
rhiniti
viru
erav
aphthoviru
genu
member
parechoviru
genu
member
insensit
itz
exclud
possibl
antivir
activ
due
toxic
side
effect
determin
effect
itz
viru
product
singl
replic
cycl
similar
multicycl
cpereduct
assay
itz
activ
emcv
erav
singl
replic
cycl
figur
without
appar
toxic
figur
itz
also
inhibit
saffold
viru
safv
replic
human
cardioviru
figur
thu
itz
exert
broad
antivir
activ
enterovirus
cardiovirus
next
determin
effect
itz
translat
replic
transfect
emcv
rna
name
subgenom
replicon
part
capsidcod
region
replac
firefli
luciferas
gene
genom
rna
emcv
renilla
luciferas
gene
insert
upstream
code
region
posit
control
use
guanidinehcl
dipyridamol
wellknown
potent
inhibitor
emcv
replic
respect
two
hour
transfect
rna
rna
replic
taken
place
yet
van
kuppeveld
et
al
luciferas
level
unaffect
indic
itz
inhibit
viral
genom
translat
figur
howev
later
time
point
luciferas
product
replicon
decreas
demonstr
itz
affect
rna
replic
importantli
itz
affect
viral
polyprotein
synthesi
process
figur
itz
wide
use
antifung
drug
inhibit
fungal
enzym
itz
also
shown
inhibitori
activ
toward
human
relat
cytochrom
addit
itz
azol
famili
antifung
drug
includ
posaconazol
ketoconazol
fluconazol
voriconazol
figur
also
inhibit
slightli
lower
similar
potenc
itz
warrilow
et
al
zhang
et
al
test
whether
drug
exert
antivir
activ
use
recombin
virus
rlucemcv
carri
renilla
luciferas
gene
upstream
code
region
posaconazol
inhibit
replic
rlucemcv
remain
azol
display
antivir
activ
concentr
similar
result
obtain
multicycl
cpereduct
assay
shown
result
rule
possibl
inhibit
underli
antivir
activ
itz
structur
relat
analog
posaconazol
itz
also
inhibit
hedgehog
hh
signal
pathway
like
interf
function
gproteincoupl
receptorlik
protein
smoothen
kim
et
al
test
sever
smoothen
antagonist
viral
luciferas
assay
smoothen
antagonist
kaadcyclopamin
chen
et
al
taipal
et
al
effect
replic
rlucemcv
figur
figur
indic
antivir
activ
itz
mediat
inhibit
hh
pathway
antiangiogen
activ
itz
attribut
least
part
inhibit
mtor
signal
pathway
disrupt
shuttl
cholesterol
plasma
membran
late
endosomeslysosom
therebi
induc
accumul
cholesterol
endolysosom
system
xu
et
al
found
cholesterol
stain
filipin
redistribut
itz
posaconazol
also
ketoconazol
inhibit
viru
replic
two
human
cell
line
figur
hela
cell
figur
moreov
mtor
inhibitor
rapamycin
effect
picornaviru
replic
beretta
et
al
wong
et
al
togeth
result
suggest
inhibit
viru
replic
itz
posaconazol
due
disrupt
endosom
cholesterol
shuttl
cholesterolrel
mtor
inhibit
addit
aforement
molecular
pathway
target
itz
itz
report
disturb
nglycosyl
nacev
et
al
howev
nglycosyl
inhibitor
tunicamycin
affect
polioviru
doeden
et
al
replic
data
shown
itz
also
shown
antagon
estrogen
receptor
cheng
et
al
agonist
affect
figur
emcv
replic
figur
final
itz
report
target
pglycoprotein
udpglucuronosyltransferas
none
like
mediat
antivir
activ
itz
potent
inhibit
ketoconazol
cheng
et
al
walski
et
al
wang
et
al
affect
viru
replic
first
step
identifi
antivir
target
itz
studi
effect
replic
mutant
virus
previous
select
resist
inhibitor
carri
mutat
confer
resist
inhibitor
eg
enviroxim
van
der
schaar
et
al
prove
less
sensit
itz
wt
singlecycl
replic
assay
figur
multicycl
cpereduct
assay
figur
mutat
shown
protect
inhibitor
ie
van
der
schaar
et
al
also
provid
crossresist
itz
figur
similarli
mutat
pv
also
shown
protect
inhibitor
arita
et
al
protect
pv
itz
figur
result
impli
link
lipid
mechan
antivir
action
itz
determin
whether
itz
inhibit
activ
transient
transfect
cell
genet
encod
ie
gfptag
ph
domain
local
sensor
specif
depend
activ
balla
et
al
van
der
schaar
et
al
control
cell
overlap
golgiloc
figur
upon
treatment
inhibitor
redistribut
cytosol
itz
howev
decreas
local
fact
itz
caus
small
increas
amount
golgiloc
appar
cell
line
stabli
express
sensor
show
homogen
moder
express
level
figur
also
upon
stain
specif
antibodi
inhibitor
van
der
schaar
et
al
decreas
level
wherea
itz
increas
level
figur
replic
complet
block
itz
see
eg
figur
thu
permit
monitor
lipid
treat
cell
untreat
itztreat
cell
infect
visual
use
antibodi
level
visual
use
antibodi
clearli
increas
compar
uninfect
cell
figur
indic
itz
also
inhibit
activ
infect
cell
rule
target
itz
next
turn
signal
step
downstream
ie
protein
bind
lipid
assess
whether
known
protein
could
target
itz
perform
target
identif
sirna
sensit
tiss
assay
arita
et
al
tiss
encompass
sirna
knockdown
candid
target
protein
potenti
biolog
effect
low
concentr
compound
among
number
golgiloc
protein
knockdown
osbp
ph
domaincontain
protein
enhanc
inhibitori
effect
low
concentr
itz
pv
replic
figur
impli
osbp
possibl
antivir
target
itz
assess
possibl
sever
experi
first
osbp
antagonist
burgett
et
al
potent
inhibit
replic
figur
confirm
pharmacolog
target
osbp
inhibit
enteroviru
replic
itz
mutat
provid
resist
figur
akin
itz
inhibit
enterovirus
test
well
emcv
erav
data
shown
importantli
affect
endolysosom
cholesterol
distribut
figur
support
previou
conclus
effect
unlik
explain
antivir
effect
itz
second
similar
pv
wang
et
al
sirna
knockdown
osbp
inhibit
replic
figur
replic
also
inhibit
osbp
knockdown
differ
statist
signific
line
lower
sensit
itz
figur
third
overexpress
osbp
restor
replic
presenc
itz
figur
confirm
inhibit
viral
replic
itz
mediat
osbp
overexpress
fail
rescu
replic
osbp
overexpress
provid
rescu
inhibitor
data
shown
indic
specif
experiment
setup
besid
osbp
also
target
burgett
et
al
knockdown
none
orp
also
sensit
pv
itz
figur
overexpress
counteract
inhibitori
effect
replic
figur
also
attempt
test
effect
deplet
although
tiss
assay
kd
potenti
effect
itz
abl
achiev
robust
knockdown
mrna
level
therefor
conclud
unambigu
whether
import
viru
replic
problem
knockdown
also
observ
other
like
due
essenti
role
cell
prolifer
surviv
charman
et
al
collect
result
indic
osbp
novel
target
itz
involv
mechan
antivir
action
replic
hcv
also
requir
osbp
inhibit
wang
et
al
line
find
enterovirus
found
itz
posaconazol
select
azol
inhibit
hcv
replic
cell
cultur
figur
ec
valu
inhibit
hcv
replic
itz
compar
obtain
enterovirus
tabl
togeth
data
clearli
demonstr
itz
inhibit
osbp
function
virus
differ
famili
depend
osbp
function
inhibit
itz
importantli
rna
virus
sensit
inhibit
osbp
dengu
viru
replic
recent
observ
insensit
wang
et
al
show
also
replic
mous
hepat
viru
coronaviru
insensit
itz
data
shown
establish
osbp
possibl
novel
target
itz
want
studi
itz
target
protein
avail
tool
focus
osbp
remaind
studi
line
publish
data
burgett
et
al
caus
massiv
recruit
overexpress
gfposbp
golgi
apparatu
mark
stain
endogen
figur
similar
reloc
observ
endogen
osbp
figur
itz
posaconazol
azol
lack
antivir
activ
redistribut
osbp
manner
similar
livecel
imag
perform
studi
dynam
gfposbp
reloc
compound
addit
compound
gfposbp
primarili
local
cytosol
golgi
pattern
faintli
visibl
minut
addit
compound
gfposbp
fluoresc
golgi
clearli
increas
cell
treat
either
itz
continu
increas
expens
cytoplasm
signal
figur
movi
previous
report
disrupt
structur
golgi
apparatu
burgett
et
al
also
observ
min
onward
gfpposit
puncta
becam
numer
time
figur
itztreat
cell
golgi
pattern
becam
affect
hour
later
appear
less
dispers
treat
cell
investig
whether
itz
block
lipid
transfer
activ
osbp
use
set
vitro
liposom
assay
mesmin
et
al
supplement
experiment
procedur
measur
transport
dehydroergosterol
dhe
figur
figur
erlik
golgilik
liposom
itz
inhibit
sterol
transfer
activ
purifi
osbp
dosedepend
manner
ic
figur
itz
posaconazol
select
azol
strongli
inhibit
dhe
transfer
transport
liposom
assay
although
less
potent
known
osbp
ligand
figur
also
observ
dosedepend
inhibit
transfer
itz
ic
figur
posaconazol
slightli
inhibit
wherea
azol
show
activ
figur
unknown
reason
stimulatori
effect
transfer
observ
depend
cholesterol
content
erlik
liposom
ic
valu
suggest
itz
potent
toward
sterol
transfer
importantli
technic
reason
sterol
shuttl
assay
perform
differ
condit
therefor
directli
compar
investig
would
need
establish
whether
itz
inde
potent
inhibit
sterol
shuttl
itz
may
inhibit
lipid
transfer
function
osbp
directli
inhibit
function
ord
transfer
lipid
indirectli
disrupt
bind
osbp
liposom
investig
whether
itz
inhibit
bind
osbp
liposom
studi
whether
interfer
interact
ffatmotif
vapa
erlik
liposom
ii
phdomain
golgilik
liposom
end
perform
liposom
floatup
experi
use
recombin
fragment
osbp
contain
phdomain
ffatmotif
aa
phffat
figur
presenc
vapa
phffat
bound
erlik
liposom
interact
disrupt
itz
figur
interact
phffat
golgilik
liposom
disrupt
itz
either
figur
likewis
vapa
interact
phffat
recruit
golgilik
liposom
also
insensit
itz
figur
togeth
liposom
floatup
assay
show
itz
interfer
bind
osbp
liposom
via
vapa
establish
whether
itz
inhibit
lipid
transfer
activ
ord
made
use
previous
establish
assay
mesmin
et
al
limit
tryptic
proteolysi
osbp
cleav
osbp
three
major
fragment
fragment
contain
phdomain
ffatmotif
two
fragment
deriv
ord
previous
shown
ordderiv
fragment
retain
lipid
transfer
activ
also
absenc
inact
fragment
mesmin
et
al
found
itz
still
inhibit
dhe
figur
figur
transfer
osbp
subject
tryptic
proteolysi
figur
result
suggest
itz
inhibit
steroland
activ
osbp
target
ord
inhibitori
effect
itz
osbp
function
minim
vitro
system
impli
itz
directli
inhibit
osbp
biochem
defin
bind
detail
measur
bind
itz
gfposbp
use
microscal
thermophoresi
molecul
complex
distribut
differ
temperatur
field
depend
size
charg
hydrat
shell
bind
itz
osbp
affect
hydrat
shell
therebi
thermophoret
behavior
itz
alter
thermophoret
profil
purifi
gfposbp
figur
dosedepend
manner
indic
direct
bind
normal
fit
data
three
independ
measur
demonstr
itz
bind
osbp
kd
nm
figur
monophas
shape
bind
curv
indic
like
singl
bind
site
itz
osbp
although
data
rule
two
site
nearli
ident
kd
test
whether
osbp
play
role
format
andor
mainten
ro
examin
local
infect
cell
uninfect
cell
osbp
mainli
distribut
throughout
cytosol
osbp
local
golgi
apparatu
figur
coloc
transgolgi
network
marker
data
shown
infect
cell
osbp
local
markedli
chang
ie
golgi
pattern
lost
osbp
appear
dispers
structur
throughout
cytoplasm
coloc
viral
protein
marker
ro
mander
coeffici
overlap
osbp
figur
examin
whether
osbp
local
ro
manner
cell
infect
replic
allow
progress
uninhibit
hr
inhibitor
ad
min
cell
process
microscopi
inhibit
decreas
coloc
osbp
mander
coeffici
wherea
treatment
itz
increas
coloc
osbp
romark
mander
coeffici
figur
enhanc
recruit
osbp
ro
upon
itz
treatment
reminisc
enhanc
golgiloc
osbp
upon
treatment
itz
osbp
inhibitor
may
therefor
caus
inhibit
remov
ro
test
directli
whether
itz
inhibit
shuttl
function
osbp
ro
cell
infect
replic
allow
progress
uninhibit
hr
itz
ad
hr
cell
process
microscopi
intens
ro
quantifi
itz
treatment
caus
strong
increas
signal
ro
increas
wherea
treatment
reduc
figur
line
effect
drug
osbp
recruit
figur
effect
observ
upon
treatment
guanidin
inhibitor
viral
protein
includ
rule
observ
effect
mere
due
inhibit
replic
thu
result
demonstr
infect
cell
itz
prevent
remov
ro
compar
observ
uninfect
cell
figur
test
whether
itz
also
inhibit
cholesterol
shuttl
ro
cell
infect
treat
similar
describ
cholesterol
visual
filipin
stain
coloc
filipin
quantifi
use
pearson
correl
coeffici
dmsotreat
cell
filipin
partial
overlap
pearson
itz
significantli
reduc
coloc
filipin
pearson
indic
itz
inhibit
redistribut
cholesterol
ro
figur
similarli
reduc
local
osbp
ro
figur
also
inhibit
cholesterol
shuttl
ro
pearson
wherea
guanidin
decreas
overlap
filipin
thu
demonstr
osbp
recruit
ro
action
itz
inhibit
cholesterol
transfer
function
osbp
infect
cell
enterovirus
alter
cellular
lipid
homeostasi
remodel
host
cell
membran
replic
organel
usurp
number
host
protein
arita
et
al
hsu
et
al
howev
yet
littl
known
underli
mechan
ident
host
factor
involv
elucid
mechan
action
inhibitor
viru
replic
proven
instrument
obtain
novel
insight
mechan
viral
replic
studi
identifi
itz
wide
use
antifung
drug
current
also
explor
anticanc
agent
novel
broadspectrum
inhibitor
enterovirus
cardiovirus
hcv
show
none
wellestablish
target
itz
ie
mtor
hh
explain
antivir
activ
instead
identifi
protein
osbp
novel
target
itz
antivir
effect
mediat
osbp
master
regul
lipid
homeostasi
mc
er
transgolgi
apparatu
exchang
cholesterol
membran
propos
control
mc
stabil
mesmin
et
al
osbp
prototyp
member
famili
orp
group
protein
whose
cellular
function
remain
poorli
understood
identifi
osbp
target
itz
pharmacolog
inhibit
sirna
knockdown
rescu
replic
overexpress
demonstr
import
protein
viru
replic
furthermor
osbp
local
ro
manner
itz
directli
bound
purifi
osbp
inhibit
cholesterol
activ
osbp
vitro
liposom
assay
also
live
uninfect
cell
itz
inhibit
transport
function
osbp
ie
transport
cholesterol
er
golgi
transport
golgi
er
lead
increas
level
golgi
therebi
caus
accumul
osbp
likewis
infect
cell
itz
increas
level
ro
lead
enhanc
recruit
osbp
inhibit
accumul
cholesterol
ro
thu
demonstr
itz
inhibit
lipid
shuttl
function
osbp
vitro
also
infect
uninfect
cell
enterovir
protein
play
critic
role
ro
format
recruit
lead
accumul
lipid
ro
arita
arita
et
al
hsu
et
al
show
osbp
subsequ
recruit
ro
via
data
indic
erro
mc
osbp
exchang
cholesterol
either
newli
synthes
er
origin
lipid
droplet
storag
pool
mobil
er
lead
accumul
cholesterol
ro
arita
find
agreement
recent
paper
suggest
osbp
shuttl
cholesterol
hrv
ro
base
inhibitori
effect
hrv
replic
osbp
knockdown
treatment
roulin
et
al
find
level
cholesterol
elev
expens
cholesterylest
ie
form
cholesterol
store
lipid
droplet
enterovirusinfect
cell
ilnytska
et
al
roulin
et
al
suggest
store
cholesterol
mobil
transport
ro
addit
uptak
cholesterol
endocytosi
suggest
contribut
accumul
cholesterol
ro
ilnytska
et
al
role
cholesterol
accumul
ro
far
establish
cholesterol
profound
import
membran
properti
membran
fluiditi
format
lipid
microdomain
therebi
like
import
membran
rearrang
deform
underli
ro
format
addit
cholesterol
alter
suggest
affect
viral
polyprotein
process
effici
ilnytska
et
al
activ
osbp
also
import
homeostasi
lipid
ergolgi
mc
act
concert
pi
transfer
protein
suppli
pi
synthesi
golgi
membran
cert
transfer
ceramid
golgi
sphingomyelin
synthesi
therebi
gener
diacylglycerol
dag
peretti
et
al
importantli
osbpligand
eg
chang
local
cert
modifi
sphingomyelin
synthesi
burgett
et
al
perri
ridgway
inhibitor
osbpmedi
lipid
shuttl
itz
may
thu
affect
accumul
cholesterol
also
perturb
homeostasi
lipid
sphingomyelin
dag
whether
contribut
inhibit
ro
format
andor
function
remain
establish
studi
work
arita
et
al
implic
role
addit
osbp
enteroviru
replic
unfortun
littl
known
biolog
function
role
propos
organ
cytoskelet
vimentin
network
cell
prolifer
surviv
sterol
transfer
charman
et
al
wang
et
al
howev
unlik
osbp
local
golgi
normal
condit
respons
ligand
charman
et
al
wang
et
al
therefor
seem
unlik
transport
cholesterol
er
golgi
similar
manner
osbp
overexpress
counteract
inhibitori
effect
itz
viru
replic
thu
remain
establish
possibl
heteromultim
wyle
et
al
import
viru
replic
requir
investig
besid
osbp
orp
appear
target
itz
though
may
still
import
viru
replic
itz
shown
inhibit
angiogenesi
via
mtor
growth
hhdepend
cancer
cell
exact
molecular
mechan
antitumor
activ
itz
await
elucid
remain
establish
whether
osbp
inhibit
contribut
anticanc
activ
itz
via
pathway
osbp
overexpress
show
counter
antivir
activ
itz
fail
prevent
inhibitori
effect
itz
mtor
hh
signal
shown
observ
suggest
itz
inhibit
antitumor
pathway
osbp
howev
exclud
overexpress
approach
neutral
antivir
effect
itz
therefor
work
need
establish
whether
itz
exert
antitumor
activ
via
osbp
andor
sever
natur
product
recent
report
inhibit
growth
cultur
human
cancer
cell
line
osbp
therefor
collect
term
orpphilin
burgett
et
al
data
itz
target
osbp
justifi
classifi
itz
novel
orpphilin
plausibl
itz
inhibit
osbp
cancer
cell
growth
surviv
manner
independ
addit
mtor
hh
recent
two
inhibitor
pv
replic
shown
target
osbp
arita
et
al
although
bind
osbp
yet
shown
may
therefor
also
classifi
orpphilin
conclus
identifi
itz
broadspectrum
inhibitor
enteroviru
cardioviru
hcv
replic
exert
antivir
activ
novel
target
osbp
presum
inhibit
lipid
shuttl
function
osbp
togeth
studi
provid
novel
insight
enteroviru
replic
present
itz
orpphilin
potenti
novel
inhibitor
treat
enteroviru
infect
detail
publish
standard
method
cell
cultur
plasmid
viru
infect
replicon
transfect
tiss
assay
rescu
experi
analysi
viral
polyprotein
process
sirna
experi
immunofluoresc
microscopi
liposom
assay
provid
supplement
experiment
procedur
follow
compound
purchas
itraconazol
santa
cruz
biotechnolog
posaconazol
merck
ketoconazol
enzo
life
scienc
fluconazol
voriconazol
pfizer
pharmek
ltd
dipyridamol
guanidin
hydrochlorid
guhcl
sigma
aldrich
tocri
bioscienc
cyclopaminekaad
calbiochem
kind
gift
dr
k
shokat
uc
berkeley
usa
macleod
et
al
provid
galapago
nv
mechelen
belgium
isol
natur
burgett
et
al
dissolv
accord
manufactur
instruct
guhcl
dissolv
water
compound
dmso
nih
clinic
collect
purchas
nih
highli
druglik
compound
screen
inhibitor
use
reduct
cpe
readout
subconflu
monolay
bgm
cell
plate
infect
ccid
per
well
compound
ad
final
concentr
level
cpe
visual
assess
two
day
incub
full
cpe
develop
infect
untreat
control
well
livecel
imag
experi
hela
cell
transfect
pegfphosbp
treat
itz
solvent
control
dmso
imag
use
nikon
confoc
laser
scan
microscop
imag
process
quantifi
use
nikon
nisel
softwar
addit
detail
see
supplement
experiment
procedur
interact
itz
recombin
gfphosbpsii
human
osbp
ntermin
gfp
ctermin
streptagii
investig
mst
use
nanotemp
monolith
instrument
ntanalysi
softwar
nanotemp
technolog
data
present
mean
sem
replic
data
analyz
pairwis
comparison
condit
use
onetail
student
ttest
statist
signific
indic
p
p
p
refer
web
version
pubm
central
supplementari
materi
f
bgm
cell
infect
wt
low
moi
presenc
itz
cell
viabil
measur
three
day
gh
vitro
transcrib
rna
subgenom
replicon
wt
indic
mutant
g
ppvfluc
wt
h
transfect
rd
cell
cell
treat
dmso
itz
inhibitor
firefli
luciferas
level
hr
pi
determin
hela
cell
transfect
treat
dmso
itz
hr
stain
antibodi
hoechst
experi
perform
triplic
shown
mean
valu
sem
asterisk
indic
statist
signific
compar
mock
treat
control
b
mutant
viru
compar
wt
scale
bar
correspond
see
also
figur
cell
transfect
sirna
target
protein
infect
pv
incub
presenc
itz
normal
pv
infect
repres
level
firefli
luciferas
activ
hr
pi
sirnatransfect
compoundtr
cell
divid
firefli
luciferas
activ
measur
sirnatransfect
untreat
cell
b
hela
cell
infect
wt
mutant
moi
treat
renilla
luciferas
level
determin
hr
cell
viabil
determin
parallel
c
cell
treat
hr
gj
effect
itz
bind
ntermin
osbp
fragment
aa
phffat
erlik
gh
golgilik
ij
liposom
examin
liposom
floatup
assay
outlin
panel
g
liposom
fraction
analyz
bind
protein
sdspage
h
j
kl
effect
itz
control
compound
dhe
k
l
transfer
trypsin
osbp
studi
fulllength
osbp
panel
af
interact
itz
gfptag
osbp
investig
use
mst
data
three
separ
measur
normal
plot
sigmoid
doserespons
curv
fit
statist
signific
drugtreat
condit
calcul
compar
drug
control
see
also
figur
bgm
cell
infect
moi
hr
pi
cell
treat
min
dmso
vehicl
control
bf
inhibitor
itz
hr
pi
cell
fix
process
immunofluoresc
antibodi
osbp
viral
protein
imag
use
clsm
b
mander
coeffici
overlap
osbp
calcul
dmso
cell
bf
cell
itz
cell
bgm
cell
infect
moi
pi
cell
treat
hr
dmso
mm
guanidin
hcl
gua
bf
itz
hr
pi
cell
fix
process
immunofluoresc
antibodi
imag
widefield
microscopi
deconvolut
b
intens
structur
calcul
dmso
cell
gua
cell
bf
cell
itz
cell
c
hela
cell
infect
moi
pi
cell
treat
hr
dmso
mm
gua
bf
itz
hr
pi
cell
fix
process
immunofluoresc
antibodi
filipin
stain
cholesterol
imag
widefield
microscopi
deconvolut
pearson
correl
coeffici
overlap
filipin
calcul
dmso
cell
gua
cell
bf
cell
itz
cell
shown
mean
sem
scale
bar
correspond
